Suppr超能文献

慢性自发性荨麻疹补充二胺氧化酶:一项随机、双盲、安慰剂对照研究。

Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study.

作者信息

Yacoub Mona-Rita, Ramirez Giuseppe A, Berti Alvise, Mercurio Giuseppe, Breda Daniela, Saporiti Nicoletta, Burastero Samuele, Dagna Lorenzo, Colombo Giselda

机构信息

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.

Università Vita-Salute San Raffaele, Milan, Italy.

出版信息

Int Arch Allergy Immunol. 2018;176(3-4):268-271. doi: 10.1159/000488142. Epub 2018 Apr 26.

Abstract

INTRODUCTION

Diamine oxidase (DAO) catabolizes and inactivates histamine, a key player in a wide range of invalidating conditions, such as migraine and chronic spontaneous urticaria (CSU). The highest expression of DAO occurs in the gastrointestinal tract, possibly to control the burden of histamine intake from food.

METHODS

Here, we tested the hypothesis that a 30-day oral supplementation with DAO (1 capsule b.i.d., 15 min before a meal) could reduce the severity of CSU as estimated by the 7-Day Urticaria Activity Score (UAS-7). The study was designed as a double-blind, placebo-controlled, crossover investigation of 22 patients with CSU incompletely controlled by first-line antihistamine therapy.

RESULTS

Twenty patients completed the study. Supplemental therapy with DAO caused a 3.8 ± 1.2 point mean ± SEM UAS-7 score reduction in patients with low serum DAO levels at time 0 (p = 0.041 compared to placebo). The degree of UAS-7 improvement was inversely correlated with the levels of basal DAO (p = 0.019). Patients receiving DAO supplementation were able to slightly reduce their daily antihistamine dose (p = 0.049).

CONCLUSION

These data suggest that DAO may be involved in the pathogenic cascade of CSU and that DAO supplementation could be effective for symptom relief in patients with low DAO levels in serum.

摘要

引言

二胺氧化酶(DAO)分解并使组胺失活,组胺是多种使人衰弱病症(如偏头痛和慢性自发性荨麻疹(CSU))中的关键因素。DAO的最高表达出现在胃肠道,可能是为了控制从食物中摄入的组胺负荷。

方法

在此,我们检验了这样一个假设,即连续30天口服补充DAO(每日两次,每次1粒胶囊,饭前15分钟服用)可降低CSU的严重程度,这是通过7天荨麻疹活动评分(UAS-7)来评估的。该研究设计为双盲、安慰剂对照、交叉试验,纳入22例一线抗组胺治疗未完全控制的CSU患者。

结果

20例患者完成了研究。对于0时血清DAO水平较低的患者,补充DAO治疗使UAS-7评分平均降低3.8±1.2分±标准误(与安慰剂相比,p = 0.041)。UAS-7改善程度与基础DAO水平呈负相关(p = 0.019)。接受DAO补充治疗的患者能够略微减少其每日抗组胺药剂量(p = 0.049)。

结论

这些数据表明,DAO可能参与了CSU的致病级联反应,并且补充DAO可能对血清DAO水平较低的患者缓解症状有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验